DDInter1089 DDInter832
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Lopinavir {u} (Compound) resembles {v} (Compound) Saquinavir
Lopinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Lopinavir {u} (Compound) binds {v} (Gene) ABCB1
Lopinavir {u} (Compound) upregulates {v} (Gene) EDEM1
Lopinavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Lopinavir {u} (Compound) downregulates {v} (Gene) GJA1
Lopinavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Lopinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Lopinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Lopinavir {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Lopinavir (Compound) resembles Saquinavir (Compound)
Lopinavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Lopinavir (Compound) binds ABCB1 (Gene)
Lopinavir (Compound) upregulates EDEM1 (Gene)
Lopinavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Lopinavir (Compound) downregulates GJA1 (Gene)
Lopinavir may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Lopinavir may lead to a major life threatening interaction when taken with Fingolimod